Sangamo Therapeutics Inc

Research Sangamo Therapeutics Inc (SGMO) on Bullrun: market cap USD 30.66M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSGMO
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 30.66M
• Financial periodFY2025
• RevenueUSD 39.55M
• Revenue growth-31.6%
• Net income-USD 122.93M
• Free cash flow-USD 97.31M

Valuation Snapshot

latest market cap is USD 30.66M.

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease;

Frequently asked questions

What is Sangamo Therapeutics Inc's market cap?

Sangamo Therapeutics Inc's market capitalization is USD 30.66M.

What does Sangamo Therapeutics Inc do?

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.